RDInnovation (Denmark) – Strategic-Technological Analysis

About this report

RDInnovation ApS (RDI) is a Danish deep-tech pharmaceutical startup focused on biotech solutions for oncology and radiation protection . The company’s proprietary drug platform (BP-Cx) is based on synthetic benzene polycarboxylic acid polymers licensed to RDI, which it uses to develop radioprotective and anticancer therapies .

RDI operates internationally (with headquarters in Copenhagen and offices in the USA and Norway) and emphasizes dual-use applications in medicine and space . Its research portfolio spans CBRN (Chemical, Biological, Radiological, Nuclear) defense countermeasures and space medicine, aligning with emerging European needs in strategic autonomy and resilience.

Key questions this report answers

• What is RDI's BP-Cx drug platform and how does it deliver radioprotective and anticancer therapies?
• How mature are RDI's CBRN countermeasures and space-medicine applications relative to European resilience needs?
• What partners and markets span RDI's Copenhagen HQ and its US and Norway offices?
• What capability gaps and dependencies define RDI's dual-use biotech strategy?

Inside this report

• Executive Summary
• 1. Corporate Identity & Legal Structure
• 2. Strategic Business Profile
• 3. Technology Portfolio Mapping
• 4. Technology Readiness Assessment
• 5. European Strategic Program Participation
• 6. Academic & Research Origins
• 7. Dual-Use Applications & European Market Strategy
• 8. Strategic Partnerships & European Industrial Alliances
• 9. European Market Focus & Operational Domains
• 10. Intellectual Property & European Innovation Assets
• 11. Leadership & European Technical Expertise
• 12. Capability and Gap Analysis
• 13. Strategic Indicators & European Innovation Metrics

Who it's for

Investors screening RDInnovation ApS (RDI), competitors and partners assessing their position, and analysts who need a sourced, structured account of the entity and its technology.

Related reports

• Neuroverse – A Deep-Tech Neurotechnology Pioneer Bridging Wellness and Defense — United States
• Nordic Brain Tech – Neurofeedback Technology for Migraine Prevention — Norway
• Syngens (Norway) – AI-Powered Synthetic Biology Platform for Strategic Autonomy — Norway
• Interact Medical Technologies: Dual-Use Rehabilitation Robotics for European Strategic Autonomy — United States
• DNA Script: Enzymatic DNA Synthesis and European Biological Sovereignty — France
• Sensible Biotechnologies: Strategic Analysis for European Autonomy — Slovakia

Methodology, format & delivery

DFM reports are built from primary and official sources — TED procurement notices, CORDIS and the EU Funding & Tenders Portal, EIB operations, the NATO Innovation Fund portfolio, SIPRI data, official budget documents and company disclosures — read together with the underlying legal texts. Sources are cited in the document; it reflects them as of its publication date (24 August 2025). You receive a 14-page PDF, watermarked to you on every page, delivered on the confirmation page and by e-mail immediately after checkout (personal link valid 72 hours, up to 5 downloads). Guest checkout, single-user licence — Terms of Sale.

Related on DFM

More Tactical reports · Military Medical Tech · Synthetic Biology · Free summary of this report · All reports

Prefer unlimited access?

Prefer unlimited access? Every report like this is included in the DFM Analysis subscription. See plans →

Get the full report — €299 →